Recombinant IP-10/CXCL10, Human 
Datasheet
COA
MSDS
SHIP
Recombinant :
Recombinant IP-10/CXCL10, Human Source :
Escherichia coli. Molecular Weight :
8.6 kDa, observed by reducing SDS-PAGE. Purity :
> 95% by SDS-PAGE and HPLC analyses. Biological Activity :
ED50 < 0.2μg/ml, measured by a cell proliferation assay of HUVEC cells in the presence of 2.5ng/ml h-VEGF, corresponding to a specific activity of > 5.0× 10ˆ3 IU/mg. Physical Appearance :
Sterile Filtered White lyophilized (freeze-dried) powder. Formulation :
Lyophilized after extensive dialysis against 50mM Tris, pH8.0. AA Sequence :
MVPLSRTVR CTCISISNQP VNPRSLEKLE IIPASQFCPR VEIIATMKKK GEKRCLNPES KAIKNLLKAV SKEMSKRSP Endotoxin :
< 0.2 EU/μg, determined by LAL method. Reconstitution :
Reconstituted in ddH2O at 100 μg/ml. Storage :
Lyophilized recombinant human IP-10/CXCL10 (rhIP-10) remains stable up to 6 months at -80°C from date of receipt. Upon reconstitution, rhIP-10 should be stable up to 2 weeks at 4°C or up to 3 months at -20°C. Usage :
This material is offered by USA Bioworld biotech for research, laboratory or further evaluation purposes. For research use only. Description :
IP-10/CXCL10 also known as CXCL10, is originally identified as an IFN-γ-inducible gene in monocytes, fibroblasts and endothelial cells. It has since been shown that IP-10 mRNA is also induced by LPS, IL-1β, TNF-α, IL-12 and viruses. Additional cell types that have been shown to express IP-10 include activated T-lymphocytes, splenocytes, keratinocytes, osteoblasts, astrocytes, and smooth muscle cells. IP-10 is also expressed in psoriatic and lepromatous lesions of skin. The mouse homologue of human IP-10, Crg-2, has been cloned and shown to share approximately 67% amino acid sequence identity with human IP-10.Recombinant human IP-10/CXCL10 (rhIP-10) produced in E. coli is a single non-glycosylated polypeptide chain containing 78 amino acids. A fully biologically active molecule, rhIP-10 has a molecular mass of 8.6kDa analyzed by reducing SDS-PAGE and is obtained by proprietary chromatographic techniques at GenScript.
Recombinant IP-10/CXCL10, Human Source :
Escherichia coli. Molecular Weight :
8.6 kDa, observed by reducing SDS-PAGE. Purity :
> 95% by SDS-PAGE and HPLC analyses. Biological Activity :
ED50 < 0.2μg/ml, measured by a cell proliferation assay of HUVEC cells in the presence of 2.5ng/ml h-VEGF, corresponding to a specific activity of > 5.0× 10ˆ3 IU/mg. Physical Appearance :
Sterile Filtered White lyophilized (freeze-dried) powder. Formulation :
Lyophilized after extensive dialysis against 50mM Tris, pH8.0. AA Sequence :
MVPLSRTVR CTCISISNQP VNPRSLEKLE IIPASQFCPR VEIIATMKKK GEKRCLNPES KAIKNLLKAV SKEMSKRSP Endotoxin :
< 0.2 EU/μg, determined by LAL method. Reconstitution :
Reconstituted in ddH2O at 100 μg/ml. Storage :
Lyophilized recombinant human IP-10/CXCL10 (rhIP-10) remains stable up to 6 months at -80°C from date of receipt. Upon reconstitution, rhIP-10 should be stable up to 2 weeks at 4°C or up to 3 months at -20°C. Usage :
This material is offered by USA Bioworld biotech for research, laboratory or further evaluation purposes. For research use only. Description :
IP-10/CXCL10 also known as CXCL10, is originally identified as an IFN-γ-inducible gene in monocytes, fibroblasts and endothelial cells. It has since been shown that IP-10 mRNA is also induced by LPS, IL-1β, TNF-α, IL-12 and viruses. Additional cell types that have been shown to express IP-10 include activated T-lymphocytes, splenocytes, keratinocytes, osteoblasts, astrocytes, and smooth muscle cells. IP-10 is also expressed in psoriatic and lepromatous lesions of skin. The mouse homologue of human IP-10, Crg-2, has been cloned and shown to share approximately 67% amino acid sequence identity with human IP-10.Recombinant human IP-10/CXCL10 (rhIP-10) produced in E. coli is a single non-glycosylated polypeptide chain containing 78 amino acids. A fully biologically active molecule, rhIP-10 has a molecular mass of 8.6kDa analyzed by reducing SDS-PAGE and is obtained by proprietary chromatographic techniques at GenScript.
Blocking peptide available as BK0112-50μgP